CVEs & Vulnerabilities of September 2025 reveal a wave of high-impact flaws that security teams cannot afford to ignore. From unauthenticated exploits in FreePBX to privilege escalation in Android and ...

AbbVie has filed for approval of a regimen based on its Venclexta therapy for previously untreated patients with chronic lymphocytic leukaemia (CLL), in combination with an AstraZeneca drug. The ...